Do analysts recommend INBS or BBLG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intelligent Bio Solutions 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate MBAI or BBLG?

MBody AI currently has a consensus price target of $10.00, suggesting a potential upside of 206.75%. Given MBody AI's stronger consensus rating and higher probable upside, analysts plainly believe MBody AI is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBody AI 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, MBAI or BBLG?

MBody AI is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBody AI N/A N/A $4.14M -$7.42 N/A Bone Biologics N/A N/A -$3.11M -$1.37 N/A

Is MBAI or BBLG more profitable?

MBody AI's return on equity of 0.00% beat Bone Biologics' return on equity. Company Net Margins Return on Equity Return on Assets MBody AI N/A N/A N/A Bone Biologics N/A -57.87% -53.65%

Do analysts rate BBLG or AEMD?

Aethlon Medical has a consensus price target of $1.50, indicating a potential downside of 75.21%. Given Aethlon Medical's stronger consensus rating and higher probable upside, analysts clearly believe Aethlon Medical is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aethlon Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings & valuation, BBLG or AEMD?

Bone Biologics is trading at a lower price-to-earnings ratio than Aethlon Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bone Biologics N/A N/A -$3.11M -$1.37 N/A Aethlon Medical N/A N/A -$7.15M -$34.97 N/A

Is BBLG or AEMD more profitable?

Bone Biologics' return on equity of -57.87% beat Aethlon Medical's return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -57.87% -53.65% Aethlon Medical N/A -123.08% -99.28%

Do analysts rate BBLG or ICCM?

IceCure Medical has a consensus price target of $30.00, indicating a potential upside of 2,627.27%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts plainly believe IceCure Medical is more favorable than Bone Biologics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IceCure Medical 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate BBLG or ZYXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bone Biologics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zynex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BBLG or ZYXI more profitable?

Bone Biologics has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Bone Biologics' return on equity of -57.87% beat Zynex's return on equity. Company Net Margins Return on Equity Return on Assets Bone Biologics N/A -57.87% -53.65% Zynex -68.35% -804.30% -36.67%

Bone Biologics (BBLG) Competitors

$0.47 0.00 (-0.43%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.47 +0.00 (+0.62%)

As of 10/9/2026 07:50 PM Eastern

Compare

BBLG vs. INBS, MBAI, AEMD, ICCM, and ZYXI

Should you buy Bone Biologics stock or one of its competitors? Bone Biologics's main competitors and comparable companies include Intelligent Bio Solutions (INBS), MBody AI (MBAI), Aethlon Medical (AEMD), IceCure Medical (ICCM), and Zynex (ZYXI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Bone Biologics compare to Intelligent Bio Solutions?

Intelligent Bio Solutions (NASDAQ:INBS) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, Intelligent Bio Solutions had 1 more articles in the media than Bone Biologics. MarketBeat recorded 2 mentions for Intelligent Bio Solutions and 1 mentions for Bone Biologics. Intelligent Bio Solutions' average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
Intelligent Bio Solutions	Neutral
Bone Biologics	Neutral

33.0% of Intelligent Bio Solutions shares are held by institutional investors. Comparatively, 34.3% of Bone Biologics shares are held by institutional investors. 1.3% of Intelligent Bio Solutions shares are held by insiders. Comparatively, 5.0% of Bone Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bone Biologics has lower revenue, but higher earnings than Intelligent Bio Solutions. Bone Biologics is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intelligent Bio Solutions	$4.22M	1.20	-$12.43M	-$9.02	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A

Bone Biologics has a net margin of 0.00% compared to Intelligent Bio Solutions' net margin of -294.88%. Bone Biologics' return on equity of -57.87% beat Intelligent Bio Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intelligent Bio Solutions	-294.88%	-175.35%	-91.25%
Bone Biologics	N/A	-57.87%	-53.65%

Intelligent Bio Solutions has a beta of 4.31, indicating that its share price is 331% more volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intelligent Bio Solutions	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bone Biologics beats Intelligent Bio Solutions on 7 of the 12 factors compared between the two stocks.

How does Bone Biologics compare to MBody AI?

MBody AI (NASDAQ:MBAI) and Bone Biologics (NASDAQ:BBLG) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

1.1% of MBody AI shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 0.5% of MBody AI shares are owned by company insiders. Comparatively, 5.0% of Bone Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MBody AI has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Bone Biologics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

In the previous week, MBody AI had 2 more articles in the media than Bone Biologics. MarketBeat recorded 3 mentions for MBody AI and 1 mentions for Bone Biologics. MBody AI's average media sentiment score of 0.00 equaled Bone Biologics'average media sentiment score.

Company	Overall Sentiment
MBody AI	Neutral
Bone Biologics	Neutral

MBody AI currently has a consensus price target of $10.00, suggesting a potential upside of 206.75%. Given MBody AI's stronger consensus rating and higher probable upside, analysts plainly believe MBody AI is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBody AI	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MBody AI's return on equity of 0.00% beat Bone Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBody AI	N/A	N/A	N/A
Bone Biologics	N/A	-57.87%	-53.65%

MBody AI is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBody AI	N/A	N/A	$4.14M	-$7.42	N/A
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A

Summary

MBody AI beats Bone Biologics on 7 of the 12 factors compared between the two stocks.

How does Bone Biologics compare to Aethlon Medical?

Bone Biologics (NASDAQ:BBLG) and Aethlon Medical (NASDAQ:AEMD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Bone Biologics' return on equity of -57.87% beat Aethlon Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-57.87%	-53.65%
Aethlon Medical	N/A	-123.08%	-99.28%

In the previous week, Bone Biologics and Bone Biologics both had 1 articles in the media. Aethlon Medical's average media sentiment score of 0.75 beat Bone Biologics' score of 0.00 indicating that Aethlon Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Bone Biologics	Neutral
Aethlon Medical	Positive

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 2.0% of Aethlon Medical shares are held by institutional investors. 5.0% of Bone Biologics shares are held by insiders. Comparatively, 0.6% of Aethlon Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aethlon Medical has a consensus price target of $1.50, indicating a potential downside of 75.21%. Given Aethlon Medical's stronger consensus rating and higher probable upside, analysts clearly believe Aethlon Medical is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aethlon Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Bone Biologics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Aethlon Medical has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market.

Bone Biologics is trading at a lower price-to-earnings ratio than Aethlon Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A
Aethlon Medical	N/A	N/A	-$7.15M	-$34.97	N/A

Summary

Bone Biologics beats Aethlon Medical on 6 of the 11 factors compared between the two stocks.

How does Bone Biologics compare to IceCure Medical?

Bone Biologics (NASDAQ:BBLG) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

In the previous week, IceCure Medical had 4 more articles in the media than Bone Biologics. MarketBeat recorded 5 mentions for IceCure Medical and 1 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 0.00 equaled IceCure Medical'saverage media sentiment score.

Company	Overall Sentiment
Bone Biologics	Neutral
IceCure Medical	Neutral

Bone Biologics has higher earnings, but lower revenue than IceCure Medical. Bone Biologics is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A
IceCure Medical	$3.95M	0.95	-$15.06M	-$8.52	N/A

Bone Biologics has a net margin of 0.00% compared to IceCure Medical's net margin of -427.67%. Bone Biologics' return on equity of -57.87% beat IceCure Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-57.87%	-53.65%
IceCure Medical	-427.67%	-174.26%	-112.58%

IceCure Medical has a consensus price target of $30.00, indicating a potential upside of 2,627.27%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts plainly believe IceCure Medical is more favorable than Bone Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IceCure Medical	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Bone Biologics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, IceCure Medical has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market.

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 5.0% of Bone Biologics shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Bone Biologics beats IceCure Medical on 8 of the 14 factors compared between the two stocks.

How does Bone Biologics compare to Zynex?

Bone Biologics (NASDAQ:BBLG) and Zynex (NASDAQ:ZYXI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

Bone Biologics has a net margin of 0.00% compared to Zynex's net margin of -68.35%. Bone Biologics' return on equity of -57.87% beat Zynex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-57.87%	-53.65%
Zynex	-68.35%	-804.30%	-36.67%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zynex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bone Biologics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Zynex has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

Zynex has higher revenue and earnings than Bone Biologics. Bone Biologics is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$3.11M	-$1.37	N/A
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A

In the previous week, Bone Biologics had 1 more articles in the media than Zynex. MarketBeat recorded 1 mentions for Bone Biologics and 0 mentions for Zynex. Bone Biologics' average media sentiment score of 0.00 equaled Zynex'saverage media sentiment score.

Company	Overall Sentiment
Bone Biologics	Neutral
Zynex	Neutral

34.3% of Bone Biologics shares are owned by institutional investors. Comparatively, 29.7% of Zynex shares are owned by institutional investors. 5.0% of Bone Biologics shares are owned by insiders. Comparatively, 49.3% of Zynex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Zynex beats Bone Biologics on 6 of the 11 factors compared between the two stocks.

Get Bone Biologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBLG vs. The Competition

Export

Metric	Bone Biologics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.29M	$5.43B	$7.16B	$13.21B
Dividend Yield	N/A	1.77%	2.53%	16.37%
P/E Ratio	-0.34	25.57	275.30	26.16
Price / Sales	N/A	83.34	635.97	107.53
Price / Cash	N/A	31.87	76.38	53.09
Price / Book	0.16	5.95	11.22	6.33
Net Income	-$3.11M	$146.18M	$3.50B	$382.15M
7 Day Performance	-1.75%	-0.28%	-0.89%	-1.40%
1 Month Performance	-16.74%	-1.88%	-4.42%	-3.47%
1 Year Performance	-80.78%	5.45%	7.03%	1.18%

Bone Biologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBLG Bone Biologics	1.001 of 5 stars	$0.47 -0.4%	N/A	-82.7%	$1.29M	N/A	N/A	2
INBS Intelligent Bio Solutions	1.4379 of 5 stars	$1.57 -1.3%	N/A	-86.5%	$5.27M	$4.22M	N/A	60	Short Interest Decrease
MBAI MBody AI	2.8941 of 5 stars	$3.01 -6.2%	$10.00 +232.2%	N/A	$4.42M	N/A	N/A	85
AEMD Aethlon Medical	1.0475 of 5 stars	$6.01 -1.0%	$1.50 -75.0%	-83.6%	$4.32M	N/A	N/A	9
ICCM IceCure Medical	3.28 of 5 stars	$1.13 -1.7%	$30.00 +2,554.9%	-96.2%	$3.94M	$3.38M	N/A	68	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBLG) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bone Biologics (BBLG) Competitors

BBLG vs. INBS, MBAI, AEMD, ICCM, and ZYXI

How does Bone Biologics compare to Intelligent Bio Solutions?

Summary

How does Bone Biologics compare to MBody AI?

Summary

How does Bone Biologics compare to Aethlon Medical?

Summary

How does Bone Biologics compare to IceCure Medical?

Summary

How does Bone Biologics compare to Zynex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bone Biologics (BBLG) Competitors

BBLG vs. INBS, MBAI, AEMD, ICCM, and ZYXI

How does Bone Biologics compare to Intelligent Bio Solutions?

Does the media favor INBS or BBLG?

Do insiders & institutionals hold more shares of INBS or BBLG?

Which has better valuation and earnings, INBS or BBLG?

Is INBS or BBLG more profitable?

Which has more risk & volatility, INBS or BBLG?

Do analysts recommend INBS or BBLG?

Summary

How does Bone Biologics compare to MBody AI?

Do insiders and institutionals hold more shares of MBAI or BBLG?

Which has more volatility and risk, MBAI or BBLG?

Does the media favor MBAI or BBLG?

Do analysts rate MBAI or BBLG?

Is MBAI or BBLG more profitable?

Which has better valuation and earnings, MBAI or BBLG?

Summary

How does Bone Biologics compare to Aethlon Medical?

Is BBLG or AEMD more profitable?

Does the media refer more to BBLG or AEMD?

Do institutionals & insiders believe in BBLG or AEMD?

Do analysts rate BBLG or AEMD?

Which has more volatility & risk, BBLG or AEMD?

Which has better earnings & valuation, BBLG or AEMD?

Summary

How does Bone Biologics compare to IceCure Medical?

Does the media refer more to BBLG or ICCM?

Which has better valuation and earnings, BBLG or ICCM?

Is BBLG or ICCM more profitable?

Do analysts rate BBLG or ICCM?

Which has more volatility and risk, BBLG or ICCM?

Do insiders and institutionals hold more shares of BBLG or ICCM?

Summary

How does Bone Biologics compare to Zynex?

Is BBLG or ZYXI more profitable?

Do analysts rate BBLG or ZYXI?

Which has more risk & volatility, BBLG or ZYXI?

Which has higher earnings and valuation, BBLG or ZYXI?

Does the media refer more to BBLG or ZYXI?

Do institutionals & insiders believe in BBLG or ZYXI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBLG vs. The Competition

Bone Biologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools